Overview

* Avanos Q3 2025 sales rose 4.3%, beating analyst expectations

* Company reported a Q3 net loss of $1.4 mln, down from $5.9 mln net income last year

* Company raises full-year revenue and adjusted EPS guidance

Outlook

* Avanos raises 2025 revenue guidance to $690 mln - $700 mln

* Avanos increases 2025 adjusted EPS guidance to $0.85 - $0.95

* Company cites tariff uncertainty affecting financial outlook

Result Drivers

* SPECIALTY NUTRITION GROWTH - Double-digit growth in SNS segment driven by demand in enteral feeding and neonate solutions

* NEXUS MEDICAL ACQUISITION - Acquisition adds complementary technology to SNS segment, expected to benefit NICU and PICU care

* PAIN MANAGEMENT MIXED RESULTS - RFA product sales grew, offset by decline in surgical pain and recovery products

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $177.80 $164.50

mln mln (1

Analyst)

Q3 Net -$1.40

Income mln

Q3 $9.50

EBITDA mln

Q3 Gross $86 mln

Profit

Q3 $100,000

Operatin

g Income

Q3 -$1.20

Pretax mln

Profit

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)